A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities

The aim of the study to evaluate the safety and efficacy of SKB571 for injection as monotherapy in patients with locally advanced or metastatic Non-Small Cell Lung Cancer with MET abnormalities. Eligible subjects will receive SKB571 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.

Trial Details

NCT ID
NCT07308106
Phase
PHASE2
Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • SKB571 for injection
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Male or female, age ≥ 18 years and ≤ 75 years at the time of signing the informed consent form (ICF).
  • Participants with histologically or cytologically confirmed NSCLC.
  • Locally advanced or metastatic NSCLC with MET Abnormalities that has progressed after standard therapy.
  • At least one measurable lesion as assessed by the investigator according to RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →